Older adults: Should the paradigm shift from standard therapy?

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 1, 2008, Pages 61-66

  Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute myelogenous leukemia; AML; beta2 macroglobulin; beta2M; chemotherapy; clinical trials delayed treatment; DAT; older adults; valproic acid

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; AZACITIDINE; BETA 2 MICROGLOBULIN; BILIRUBIN; CREATININE; CYTARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; BILIRUBIN BLOOD LEVEL; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG RESPONSE; ELDERLY CARE; EXPERIMENTAL THERAPY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA REMISSION; LOW DRUG DOSE; MEDICAL DECISION MAKING; MONOTHERAPY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK BENEFIT ANALYSIS;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PATIENT CARE PLANNING; REMISSION INDUCTION; THERAPIES, INVESTIGATIONAL;

EID: 40749100948     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.11.006     Document Type: Review

References (10)

1. Beran M., Luthra R., Kantarjian H., et al. FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leukemia Research 28 (2004) 547-550
2. Kantarjian H., O'Brien S., Cortes J., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106 (2006) 1090-1098
3. Estey E., Smith T.L., Keating M.J., et al. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 3 (1989) 257-263
4. Anderson J.E., Kopecky K.J., Willman C.L., et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 100 (2002) 3869-3876
5. Appelbaum F.R., Kopecky K.J., Tallman M.S., et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. British Journal of Haematology 135 (2006) 165-173
6. Rowe J.M., Neuberg D., Friedenberg W., et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103 (2004) 479-485
7. Tsimberidou A.M., Kantarjian H.M., Keating M.J., et al. Prognostic significance of ß-2 microglobulin levels in acute myeloid leukemia: analysis of 1293 patients. Blood 108 (2006) 240a [abstract 802]
8. Bataille R., Grenier J., and Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment-a prospective study of 160 patients. Blood 63 (1984) 468-476
9. Giles F.J., Bekele B.N., O'Brien S., et al. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. British Journal of Haematology 121 (2003) 578-585
10. Albitar M., Johnson M., Do K.A., et al. Levels of soluble HLA-I and beta2 M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia 21 (2007) 480-488